Prostate Cancer Landmark Studies
Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4)
Prostate Cancer Intervention versus Observation Trial (PIVOT)
Prostate Testing for Cancer Treatment (PROTECT)
- Bill-Axelson, Anna, et al. "Radical prostatectomy or watchful waiting in early prostate cancer." New England Journal of Medicine 370.10 (2014): 932-942.
- Bill-Axelson, Anna, et al. “Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-Up.” The New England Journal of Medicine, vol. 379, no. 24, 2018, pp. 2319–2329.
Prostate Cancer Intervention versus Observation Trial (PIVOT)
- Wilt, Timothy J., et al. "Radical prostatectomy versus observation for localized prostate cancer." New England Journal of Medicine 367.3 (2012): 203-213.
- Wilt, Timothy J., et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England Journal of Medicine, vol. 377, no. 2, 2017, pp. 132–142.
- Wilt, Timothy J., et al. "Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)." European urology (2020).
Prostate Testing for Cancer Treatment (PROTECT)
Enazalutamide
AFFIRM - enzatludamide vs. placebo in mCRPC following chemotherapy
PREVAIL - enzalutamide vs. placebo in chemotherapy naive mCRPC
TERRAIN - enzalutamide vs. bicalutamide in chemotherapy naive mCRPC
PROSPER - enzalutamide vs. placebo in non-metastatic CRPC
ARCHES - enzaluatmide vs. placebo in mCSPC
PREVAIL - enzalutamide vs. placebo in chemotherapy naive mCRPC
TERRAIN - enzalutamide vs. bicalutamide in chemotherapy naive mCRPC
PROSPER - enzalutamide vs. placebo in non-metastatic CRPC
ARCHES - enzaluatmide vs. placebo in mCSPC
PREVAIL - Hussain, Maha, et al. "Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer." New England Journal of Medicine 378.26 (2018): 2465-2474.
PROSPER - Sternberg, Cora N., et al. "Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer." New England Journal of Medicine 382.23 (2020): 2197-2206.
ARCHES - Armstrong, Andrew J., et al. "ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer." Journal of Clinical Oncology 37.32 (2019): 2974.
PROSPER - Sternberg, Cora N., et al. "Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer." New England Journal of Medicine 382.23 (2020): 2197-2206.
ARCHES - Armstrong, Andrew J., et al. "ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer." Journal of Clinical Oncology 37.32 (2019): 2974.